@brianjarvis
Keytruda has really not been shown to be successful with prostate cancer patients. People can try it, but I have not heard of anybody that had success with it.

Proveng Is a useful thing to do, but it is recommended to do the procedure when people’s PSA is very low. If someone is facing the last treatments, their PSA is probably not very low. The actual success of Proveng, in giving someone a long-term overall survival, is not always great. It’s definitely worth getting if you do it early.

Provenge (sipuleucel-T) is a generally successful, FDA-approved immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Studies show it extends median survival by approximately 4.1 months, reduces the risk of death by 22.5%, and, in real-world data, has shown potential to prolong survival by over 14 months.

Survival Benefit: Clinical trials indicated that 31.7% of patients treated with Provenge were alive after 3 years, compared to 21.7% in the control group.

Optimal Candidates: The treatment is most effective for men with lower PSA levels, as it is designed for earlier stages of advanced disease before significant pain or symptoms develop.